TRACER Developmental Research Program

TRACER发展研究计划

• 批准号: 10290166
• 负责人: VICTORIA L. SEEWALDT
• 金额: $ 17.23万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10290166
• 关键词: Academic Medical Centers; Address; African American; Air Pollution; Asians; Basic Science; Behavioral; Behavioral Research; California; Cancer Center; Catchment Area; Center for Translational Science Activities; Characteristics; Cities; City of Hope Comprehensive Cancer Center; Clinical Treatment; Clinical Trials; Collaborations; Communities; Community based prevention; Core Facility; Country; Data; Development; Diagnostic; Ensure; Epidemiology; Ethnic Origin; Evaluation; Face; Financial Support; Fostering; Funding; Future; Geography; Goals; Grant; Hispanics; Human; Individual; Institution; Intervention; Latinx; Leadership; Los Angeles; Malignant neoplasm of lung; Medical; Monitor; National Cancer Institute; Outcomes Research; Pilot Projects; Population; Population Heterogeneity; Poverty; Process; Program Research Project Grants; Race; Reporting; Research; Research Personnel; Research Project Grants; Resources; Rural; Sampling; Shapes; Site; Smoking; South Carolina; Translating; Translational Research; Universities; Virginia; Woman; black men; cancer health disparity; epidemiology study; health disparity; innovation; men; non-smoking; preventive intervention; programs; racial and ethnic; rural area; success; urban area

DEVELOPMENTAL RESEARCH PROGRAM: PROJECT SUMMARY The Developmental Research Program (DRP) within this P20 Translational Research Center in Lung Cancer Disparities (TRACER) application aims to select and support highly promising and innovative pilot research projects to reduce health disparities in lung cancer. The TRACER MPI and DRP leadership (representing the 3 participating National Cancer Institute-designated cancer centers at Virginia Commonwealth University, Medical University of South Carolina, and City of Hope) have set clear priorities for the selection of pilot research projects. These priorities are (1) projects demonstrating exceptional translational science potential, (2) projects inclusive of vertical and horizontal collaborations between the 3 participating institutions, and (3) projects with maximum impact on the diverse communities serving—Virginia, South Carolina, and southern California. These pilot research projects may include basic research explorations using human samples, diagnostic or treatment clinical interventions in the form of clinical trials, or community-based prevention interventions. A major advantage of this 3-institution P20 TRACER collaborative is that it provides immediate access to distinct urban and rural regions with vastly different racial/ethnic compositions as well as cultural and environmental characteristics that likely contribute to the disparities reported in lung cancer (e.g., large African American/Black populations in Virginia and South Carolina and large Hispanic/LatinX and Asian populations in southern California, high rates of smoking in Virginia and South Carolina; high levels of air pollution in southern California). The DRP will provide direct and significant financial support for competitively selected pilot research projects and will provide these pilot project PIs or investigative teams with access to the expertise and resources of the TRACER-supported cores and an extraordinary list of other cutting-edge resources available within the 3 participating institutions. The leaders of the DRP will select and fund a minimum of 3 pilot research projects annually, and the projects’ progress will be carefully monitored by multi-levels of internal and external scientific and community advisors. The ultimate goal of the DRP is to establish a pipeline of research focused on the multi-dimensional causes of lung cancer disparities within the diverse populations served by the partnering institutions and to develop the preliminary data to support competitive research projects for a future, collaborative P50 SPORE application.

发展研究计划：项目摘要 该P20转化研究中心的发展研究计划（DRP） 差异（Tracer）应用程序旨在选择和支持高度有前途和创新的试点研究 减少肺癌健康差异的项目。 Tracer MPI和DRP领导（代表3 参加弗吉尼亚联邦大学的国家癌症研究所指定的癌症中心 南卡罗来纳大学和希望之城）为选择试点研究项目设定了明确的优先事项。 这些优先事项是（1）证明具有特殊转化科学潜力的项目，（2）包括 这三个参与机构之间的垂直和水平合作，以及（3）最高的项目 对服务的潜水员社区的影响 - Virginia，南卡罗来纳州和南加州。这些飞行员 研究项目可能包括使用人类样品，诊断或治疗临床的基础研究探索 以临床试验或基于社区的预防干预形式进行干预措施。一个主要优势 这个三个机构P20示踪剂的合作是，它可以立即访问不同的城市和农村 种族/族裔组成截然不同的地区以及文化和环境特征 可能导致肺癌报告的差异（例如，大型非裔美国人/黑人人群 弗吉尼亚州和南卡罗来纳州以及南加州的大型西班牙裔/拉丁裔和亚洲人口 在弗吉尼亚州和南卡罗来纳州吸烟；南加州的高空气污染）。 DRP将提供 为竞争性选择的试点研究项目的直接和大量财政支持，并将提供这些 PIS Project PI或调查团队，可以使用示踪剂支持的专业知识和资源 核心和三个参与机构中提供的其他尖端资源的非凡列表。 DRP的领导人每年将至少选择3个试点研究项目，这些项目的项目和这些项目的资金 内部和外部科学和社区顾问的多层次将仔细监控进度。 DRP的最终目标是建立一条研究渠道，重点是 伙伴机构服务的潜水员种群中的肺癌差异，并发展 初步数据，以支持未来的协作P50孢子应用程序的竞争性研究项目。